Darvon was a brand name for propoxyphene, a synthetic opioid painkiller that became one of the most widely prescribed drugs in the United States from the 1960s onward. The U.S. Food and Drug Administration pulled it from the market in November 2010, primarily because the drug could cause dangerous heart rhythm disturbances even at recommended doses. But the path from blockbuster analgesic to banned substance took decades, marked by mounting overdose deaths, contested evidence about the drug’s actual effectiveness, and repeated failed attempts at regulatory intervention.
What Darvon Was and How It Worked
Propoxyphene is a synthetic compound structurally related to methadone. It acts on opioid receptors in the brain to blunt the perception of pain, much like other opioids, but with considerably weaker potency. It was classified as a “Step 2” analgesic under the World Health Organization’s pain ladder, meaning it occupied the middle ground between basic painkillers like aspirin and stronger opioids like morphine.1Elsevier. A Drug Utility Analysis of the Withdrawal of the Propoxyphene–acetaminophen Combination from a Teaching Hospital in Taiwan Doctors prescribed it for mild to moderate pain from headaches, post-surgical recovery, and bone fractures.
Eli Lilly introduced Darvon (propoxyphene hydrochloride) in the late 1950s, and it quickly became enormously popular. Between 1960 and 1973, Darvon and its related products were the most frequently prescribed brand-name pharmaceuticals in the entire United States.2Tax Notes Research. Tax Court Reallocates Income From Eli Lilly’s Puerto Rico Affiliate for Darvon Sales A key selling point was the claim that propoxyphene provided pain relief with only “negligible potential of addiction,” which made it attractive to physicians wary of prescribing stronger narcotics. The drug was also sold in combination with acetaminophen under the brand name Darvocet, which became even more commonly prescribed than Darvon alone.
The Addiction Claims That Turned Out to Be Wrong
The marketing of propoxyphene as essentially non-addictive was one of the drug’s most consequential features, and the science eventually showed it was misleading. As early as 1969, case reports began documenting genuine physical dependence. One published case described a woman who, after being introduced to the drug following surgery, escalated her daily dose to 2,300 milligrams. When researchers substituted placebos, she developed clear withdrawal symptoms, confirming that tolerance and physical dependence to propoxyphene could develop.3Annals of Internal Medicine. Propoxyphene (Darvon®) Addiction and Withdrawal Syndrome
The problem went well beyond individual cases. Between 1969 and 1971, nonmedical use of propoxyphene among U.S. Army soldiers stationed in West Germany reached what researchers described as epidemic proportions. The major complications observed included respiratory arrest, psychotic reactions, and physical addiction. Thirteen soldiers died from overdoses, with pulmonary edema found as the primary cause at autopsy. Some soldiers injected the drug intravenously, which proved especially destructive to veins and soft tissues, limiting injection-route addiction to roughly twelve weeks before the damage made it physically impossible to continue.4JAMA Internal Medicine. Complications of Propoxyphene Abuse
By 1981, researchers writing in medical journals were blunt about the gap between marketing and reality. While propoxyphene was probably less addictive than stronger narcotics on a user-by-user basis, its wide availability by prescription and low cost compared to illegal opiates made it a prime target for abuse. Both psychological dependence and physical withdrawal had been documented internationally.5PubMed. Propoxyphene dependence: an update The initial promise of “safe” pain relief was, at best, overstated.
A Troubling Pattern of Overdose Deaths
Propoxyphene’s narrow margin between a therapeutic dose and a lethal one was recognized surprisingly early. A ten-year study of fatal propoxyphene overdoses identified 81 deaths, of which about three-quarters were suicides and roughly a quarter were accidental.6PubMed. Deaths related to propoxyphene overdose: a ten-year assessment The drug’s toxicity in overdose was disproportionate to its relatively modest pain-relieving power, which meant that a patient who took a handful of pills in a moment of crisis, or who simply miscounted doses, faced a much higher risk of death than with many other painkillers.
The combination products posed a particular problem. Darvocet paired propoxyphene with acetaminophen, which meant an overdose delivered a double hit: the opioid effects of propoxyphene plus the severe liver toxicity of acetaminophen. This combination made accidental poisonings especially dangerous and complicated treatment for emergency physicians.
The sheer volume of prescriptions amplified the body count. With tens of millions of prescriptions written annually at its peak, even a relatively low per-prescription risk translated into hundreds of deaths per year across the country. By the time the drug was finally pulled, propoxyphene-involved deaths in Florida alone numbered in the hundreds annually.
Early Warnings That Failed to Stick
The FDA did not ignore propoxyphene’s dangers for the entire half-century the drug was on the market, but its interventions were strikingly ineffective. In 1978 through 1980, the agency launched an informational campaign in partnership with Eli Lilly that included mailed warnings to prescribers, face-to-face education, press releases, and labeling changes. A recommendation was added against giving patients refills without reassessment.
The results were discouraging. Propoxyphene prescribing had already been declining by about eight percent per year before the warnings, and during the campaign it continued dropping at roughly the same rate. After the warnings ended, even that pre-existing decline stalled. The no-refill recommendation had no measurable impact on refill rates. And the risk of overdose death per prescription filled stayed essentially flat from 1979 onward.7PubMed Central. Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene The researchers concluded that reducing misuse of drugs like propoxyphene would require “stronger, more sustained regulatory or educational measures” than voluntary warnings. That conclusion would prove prophetic, though it took three more decades to act on.
The Heart Problem That Sealed Darvon’s Fate
Propoxyphene had been killing people through respiratory depression for years, the classic opioid overdose mechanism. But the final push toward withdrawal came from a different direction: the drug’s effects on the heart. Laboratory studies showed that propoxyphene blocked sodium channels in cardiac cells in a way that disrupted electrical conduction. This blocking effect recovered slowly, meaning the drug accumulated its cardiac impact over time.8PubMed Central. Marked QRS complex abnormalities and sodium channel blockade by propoxyphene reversed with lidocaine On an electrocardiogram, this showed up as widened QRS complexes, a sign that the heart’s electrical signals were taking abnormally long to travel through the ventricles.
The FDA ultimately acted after reviewing data showing that propoxyphene could prolong the QT interval and increase the risk of ventricular arrhythmias, a type of chaotic heart rhythm that can be fatal.9PubMed Central. Synthetic opioids and arrhythmia risk: a new paradigm? What made this finding especially damning was that these cardiac effects could occur at doses close to what doctors were prescribing, not just in massive overdoses. An elderly patient with slowed drug metabolism, or someone taking other medications that competed for the same liver enzymes, could reach dangerous propoxyphene levels without realizing it.
Interestingly, a large observational study published after the withdrawal found that propoxyphene users did not have a significantly elevated rate of sudden cardiac death compared to nonusers or to people taking hydrocodone. What they did have was a roughly 85% higher risk of medication toxicity deaths compared to nonusers. Because toxicity deaths were a small fraction of total deaths in the study, overall out-of-hospital mortality differed by less than ten percent between groups and was not statistically significant.10PubMed Central. Propoxyphene and the Risk of Out-of-Hospital Death This finding added nuance to the story: the cardiac risk may have been most acute in overdose situations rather than at strictly therapeutic doses, though the FDA had already decided the overall risk-benefit ratio was unacceptable.
Europe Moved First
The United States was not the first jurisdiction to pull propoxyphene. In 2005, the European Medicines Agency recommended a gradual withdrawal of co-proxamol, the European formulation combining dextropropoxyphene with paracetamol (acetaminophen), across the entire European Union. The review concluded that the drug carried an increased risk of fatal overdose, both accidental and intentional. The United Kingdom’s Medicines and Healthcare products Regulatory Agency announced a phased withdrawal of co-proxamol in January 2005 and completed the process by the end of 2007.11PubMed Central. Dextropropoxyphene ban in India: Is there a case for reconsideration?
The European action put pressure on U.S. regulators. If the same drug had been deemed too dangerous for European patients, the argument for keeping it available in America required increasingly strained reasoning. The FDA convened advisory panels, requested additional safety data from the manufacturer (by then Xanodyne Pharmaceuticals, which had acquired the Darvon line), and eventually issued its withdrawal request in November 2010. India also banned dextropropoxyphene, though debate about whether that decision was fully justified continued in the Indian medical literature.
What Happened After Darvon Disappeared
The withdrawal created an immediate practical problem: millions of Americans had been taking propoxyphene, and they needed something else. Tracking what happened to those patients reveals both the success and the limitations of removing a drug from the market.
Following the withdrawal, former propoxyphene users experienced an abrupt drop of about 69% in their average daily opioid dose. Roughly a third of them stopped taking opioids entirely. Among those who switched to a different painkiller, tramadol and hydrocodone were the most common substitutes.12PubMed Central. Response to Propoxyphene Market Withdrawal: Analgesic Substitutes, Doses, and Adverse Events The fact that so many patients simply stopped opioids without apparent crisis reinforced what critics had long suspected: propoxyphene had been overprescribed for conditions that did not necessarily require an opioid at all.
The impact on mortality was dramatic. An analysis of propoxyphene-involved deaths in Florida found that fatalities dropped by 84% after the drug left the market, falling from 580 deaths to 92.13PubMed. Fatal poisonings involving propoxyphene before and after voluntary withdrawal from the United States’ market: An analysis from the state of Florida Some of the remaining deaths likely involved stockpiled medication. The decline confirmed that removing the drug from pharmacy shelves did what decades of warnings had not accomplished.
Why Darvon’s Story Still Matters
Propoxyphene’s trajectory from America’s most prescribed drug to banned substance is often cited as an early chapter in the broader opioid crisis narrative, though the comparison requires some care. Darvon was a weak opioid, and its primary danger was a narrow therapeutic index rather than the intense euphoria and high addiction rates associated with drugs like oxycodone. Still, the pattern is recognizable: a drug marketed as safer than its predecessors, prescribed far more widely than the evidence justified, with regulators slow to act on accumulating harm.
One lesson from the propoxyphene saga is that voluntary safety measures and informational campaigns have limited power when a drug is already deeply embedded in prescribing habits. The 1978-80 warning campaign barely dented the overdose rate.7PubMed Central. Effect of government and commercial warnings on reducing prescription misuse: the case of propoxyphene Only actual removal from the market produced a sharp decline in deaths. That finding has echoed through subsequent debates about how aggressively regulators should act when a widely used drug turns out to be more dangerous than originally believed.
The Effectiveness Debate
A question that lingered throughout propoxyphene’s long decline was whether it even worked well enough to justify any risk. Multiple studies over the years struggled to demonstrate that propoxyphene was meaningfully superior to acetaminophen or aspirin alone for mild to moderate pain. If the drug’s pain-relieving ability was roughly equivalent to over-the-counter alternatives, then any additional risk from opioid side effects, addiction potential, or cardiac toxicity was pure downside.
This framing helped regulators justify the ban even in the face of arguments that the absolute cardiac risk at therapeutic doses might be small. A drug does not need to be dramatically dangerous to warrant removal; it only needs to offer insufficient benefit relative to its harms. Propoxyphene’s weak analgesic profile meant that bar was never particularly high to begin with. When the cardiac findings arrived on top of the overdose data, the addiction evidence, and the questionable efficacy, the cumulative case was overwhelming even if no single element would have been sufficient on its own.
Patients Who Felt Abandoned
Not everyone agreed with the ban. Some chronic pain patients who had taken Darvocet for years felt that the drug worked for them when alternatives did not, and resented having their treatment yanked away by regulatory fiat. Elderly patients in particular had sometimes been prescribed propoxyphene specifically because it was perceived as gentler than stronger opioids, and the switch to hydrocodone or tramadol was not always seamless.
The prescribing data after the withdrawal tells part of this story. While a third of former propoxyphene users stopped opioids altogether, the remaining two-thirds still needed pain management and were shifted to other medications.12PubMed Central. Response to Propoxyphene Market Withdrawal: Analgesic Substitutes, Doses, and Adverse Events Some of those substitute drugs, particularly hydrocodone, carried their own addiction and overdose risks. Whether the net effect on public health was positive depends partly on how you weigh the clear reduction in propoxyphene-specific deaths against any uptick in harms from replacement opioids. The Florida mortality data, showing an 84% decline in propoxyphene-involved deaths, suggests the trade was worthwhile at a population level, but individual patients who had stable, long-term regimens disrupted had a legitimate grievance about how the transition was managed.
Generic Propoxyphene and Lingering Supply
By the time of the ban, the original Darvon brand had passed through several corporate hands and most propoxyphene on the market was generic. The withdrawal applied to all propoxyphene-containing products, not just branded versions, which meant the entire supply chain had to be unwound. Pharmacies pulled stock from shelves, and the FDA requested that patients return unused medication.
Despite this, propoxyphene continued to show up in post-ban toxicology reports for several years, as hoarded or forgotten pills turned up in medicine cabinets. The Florida study documenting the 84% decline in deaths examined the period after withdrawal and still found 92 propoxyphene-involved fatalities, a reminder that removing a drug from the market does not make it vanish overnight.13PubMed. Fatal poisonings involving propoxyphene before and after voluntary withdrawal from the United States’ market: An analysis from the state of Florida Old prescriptions, pills passed between family members, and international sources all contributed to a long tail of exposure that only gradually faded.